NASDAQ:XTLB XTL Biopharmaceuticals Q4 2025 Earnings Report $2.74 -0.07 (-2.32%) As of 10:52 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast XTL Biopharmaceuticals EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AXTL Biopharmaceuticals Revenue ResultsActual Revenue($0.26) millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AXTL Biopharmaceuticals Announcement DetailsQuarterQ4 2025Date6/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile XTL Biopharmaceuticals Earnings HeadlinesXTL Biopharmaceuticals (NASDAQ:XTLB) Stock Passes Above Fifty Day Moving Average - Should You Sell?August 12 at 3:20 AM | americanbankingnews.comXTL Biopharmaceuticals (NASDAQ:XTLB) Stock Crosses Above 50-Day Moving Average - Here's WhyAugust 4, 2026 | americanbankingnews.comWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, a sign of where AI infrastructure spending is heading next. Anthropic remains private, but one publicly traded vehicle holds it as its largest position, alongside stakes in Databricks and Anduril. It trades through any standard brokerage account.August 14 at 1:00 AM | The Oxford Club (Ad)XTL Biopharmaceuticals Ltd. Sponsored ADRJuly 8, 2026 | cnn.comXTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) After-HoursJuly 1, 2026 | nasdaq.comXTL Biopharmaceuticals Completes Acquisition of Psyga Bio to Establish Psychedelic Biotechnology PlatformJune 30, 2026 | quiverquant.comQSee More XTL Biopharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email. Email Address About XTL BiopharmaceuticalsXTL Biopharmaceuticals (NASDAQ:XTLB) engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.View XTL Biopharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
